Boundless Bio Eyes Nasdaq with Innovative Cancer Treatment Approach
March 6, 2024
Boundless Bio, a San Diego-based biotech startup, has announced its intention to go public on the Nasdaq under the ticker “BOLD.” The company, founded five years ago and part of ARCH Venture Partners’ portfolio, has raised approximately $250 million in private funding. With its innovative strategy focusing on extrachromosomal DNA (ecDNA) as a target for cancer treatment, Boundless Bio is preparing for early safety and efficacy data from its first clinical trial. The trial involves an oral CHK1 inhibitor, BBI-355, with anticipated efficacy data this year and plans for preliminary data from a second candidate, BBI-825, in 2025. Boundless Bio’s approach could potentially establish a new category in cancer therapeutics. The company, which spent $42.6 million on R&D in 2023, remains financially robust, with $120 million in cash and equivalents. Its move to go public follows successful IPOs by other biotech firms, signaling a growing interest in innovative cancer treatments.
To read more, click here.
[Source: Endpoints, March 6th, 2024]
